Literature DB >> 17197582

Association of lymphadenectomy and survival in stage I ovarian cancer patients.

John K Chan1, Elizabeth G Munro, Michael K Cheung, Amreen Husain, Nelson N Teng, Jonathan S Berek, Kathryn Osann.   

Abstract

OBJECTIVE: To estimate the survival impact of lymphadenectomy in women diagnosed with clinical stage I ovarian cancer.
METHODS: Demographic and clinicopathologic information were obtained from the Surveillance, Epidemiology and End Results Program between 1988 and 2001. Data were analyzed using Kaplan-Meier methods and Cox proportional hazards regression.
RESULTS: A total of 6,686 women had clinical stage I ovarian cancer (median age 54 years, range 1-99). Of this total, 75.9% of patients were Caucasian, 8.3% were Hispanic, 5.8% were African American, and 7.3% were Asian. Epithelial tumors were present in 85.8% of the women, and 2,862 (42.8%) patients underwent lymphadenectomy. Patients aged 50 years or more were less likely to undergo lymphadenectomy compared with their younger cohorts (39.8% compared with 60.2%, P<.001). Only 32.7% of African-American women had lymphadenectomy compared with 42.7% of Caucasian women, 47.2% of Hispanics, and 48.8% of Asians (P<.001). Lymphadenectomy was associated with improved 5-year disease-specific survival of all patients from 87.0% to 92.6% (P<.001). More specifically, lymphadenectomy improved the survival in those with non-clear cell epithelial ovarian cancer (85.9% to 93.3%, P<.001) but not in those with clear cell carcinoma, germ cell tumors, sex cord stromal tumors, and sarcomas. Moreover, the extent of lymphadenectomy (0 nodes, less than 10 nodes, and 10 or more nodes) increased the survival rates from 87.0% to 91.9% to 93.8%, respectively (P<.001). On multivariable analysis, the extent of lymphadenectomy was a significant prognostic factor for improved survival, independently of other factors such as age, stage, histology, and grade of disease.
CONCLUSION: Our data suggest that women with stage I non-clear cell ovarian cancers who underwent lymphadenectomy had a significant improvement in survival. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Year:  2007        PMID: 17197582     DOI: 10.1097/01.AOG.0000249610.95885.ef

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  34 in total

Review 1.  Current Strategy for the Treatment of Ovarian Germ Cell Tumors: Role of Extensive Surgery.

Authors:  Jin Li; Xiaohua Wu
Journal:  Curr Treat Options Oncol       Date:  2016-08

Review 2.  Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.

Authors:  Yvonne Collins; Kevin Holcomb; Eloise Chapman-Davis; Dineo Khabele; John H Farley
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

3.  Clinical and prognostic value of the presence of irregular giant nuclear cells in pT1 ovarian clear cell carcinoma.

Authors:  Naoki Matsumoto; Takashi Umezawa; Toru Sasaki; Kuninobu Nakajima; Yukiko Kanetsuna; Hiroshi Sasaki
Journal:  Pathol Oncol Res       Date:  2011-01-28       Impact factor: 3.201

4.  Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group.

Authors:  Takafumi Oshita; Hiroaki Itamochi; Ryuichiro Nishimura; Fumitaka Numa; Kazuhiro Takehara; Masamichi Hiura; Hirotoshi Tanimoto; Jun Noma; Ryoji Hayase; Akihiro Murakami; Hideo Fujimoto; Yasunobu Kanamori; Fuminori Kitada; Keiji Shitsukawa; Makoto Nagaji; Yukihisa Minagawa; Michihisa Fujiwara; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2012-10-17       Impact factor: 3.402

5.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

6.  Obesity does not affect the number of retrieved lymph nodes and the rate of intraoperative complications in gynecologic cancers.

Authors:  Mehmet Coskun Salman; Alp Usubutun; Tulay Ozlu; Kubra Boynukalin; Kunter Yuce
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

7.  Management of a suspicious adnexal mass: a clinical practice guideline.

Authors:  J E Dodge; A L Covens; C Lacchetti; L M Elit; T Le; M Devries-Aboud; M Fung-Kee-Fung
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

8.  The influence of conservative surgical practices for malignant ovarian germ cell tumors.

Authors:  John K Chan; Krishnansu S Tewari; Sarah Waller; Michael K Cheung; Jacob Y Shin; Kathryn Osann; Daniel S Kapp
Journal:  J Surg Oncol       Date:  2008-08-01       Impact factor: 3.454

9.  Evaluation of intraoperative and postoperative complications related to lymphadenectomy in ovarian cancer patients.

Authors:  Leszek Jaroslaw Gmyrek; Joanna Jonska-Gmyrek; Piotr Sobiczewski; Grzegorz Panek; Mariusz Bidzinski
Journal:  Oncol Lett       Date:  2011-03-21       Impact factor: 2.967

Review 10.  Global ovarian cancer health disparities.

Authors:  Ganna Chornokur; Ernest K Amankwah; Joellen M Schildkraut; Catherine M Phelan
Journal:  Gynecol Oncol       Date:  2012-12-22       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.